redemption code lol646

redemption code lol646 Emily Atack has shared a rare photo of her son Barney and he has grown a lot since the last time he appeared on social media. The 34-year-old former Inbetweeners star, who has set tongues wagging with her performance in Disney+ drama Rivals, welcomed her baby boy in June with Alistair Garner, her scientist boyfriend. Now, four months later, the actress has shown off Barney to her followers as he cuddles into his mum while wearing denim dungarees. It was this time last year, just ahead of Christmas , that Emily shared that she was pregnant, showing off her growing bump, and now she is fully in the swing of motherhood as Barney gets ready to enjoy his first festive season. The photo comes after Emily spoke about a scary moment during her pregnancy when she had a haemorrhage and started losing blood. Emily said: "I saw blood in the toilet and I was like, 'oh my god, I'm miscarrying' - it was just coming out of me and I thought that's it, biggest fear realised, I'm having a miscarriage." Speaking to Jamie Laing on his Great Company podcast, the actress shared: "I had a scan and he [the doctor] said 'the baby's fine, you've had a haemorrhage, a hematoma but the baby's ok'. I couldn't believe it, I thought there's no way - I thought it was all over and I thought having to tell everybody, you feel like you're letting them all down, it's really awful." She continued: "I don't want to upset anyone who's been through baby loss, miscarriage but it's the most horrific thing ever. And a lot of that pain comes from feeling like you're going to have to let everybody down, because you've told them you're going to have this baby and it's going to be wonderful and then you're having to take that away. The pressure is ridiculous." Emily also shared her dislike for how miscarriages are "dismissed as a casual thing". She said: "It's so like 'I know this girl who had a miscarriage...' because it's technically seen as common. But what is so awful, I get really angry even when doctors say it in the early days of your pregnancy, they talk about miscarriage like it is such a common thing. "That it's so flippant and so throwaway. But to that person who has just lost that baby it is the most devastating thing you could ever imagine. You have lost your child. But for some reason there's this really casual narrative, like it's so common that it's something you just sometimes have to go through. I can't even imagine the agony and it's just as women something that we are told to get on with." Follow Mirror Celebs on TikTok , Snapchat , Instagram , Twitter , Facebook , YouTube and Threads .

Colorado Avalanche (12-9, in the Central Division) vs. Tampa Bay Lightning (10-7-2, in the Atlantic Division) Tampa, Florida; Monday, 7 p.m. EST BOTTOM LINE: The Colorado Avalanche are looking to extend a three-game win streak with a victory against the Tampa Bay Lightning. Tampa Bay has a 10-7-2 record overall and a 6-2-1 record in home games. The Lightning have scored 68 total goals (3.6 per game) to rank 10th in NHL play. Colorado is 12-9 overall and 6-3-0 on the road. The Avalanche have an 8-5-0 record in games they have fewer penalties than their opponent. The teams play Monday for the second time this season. The Lightning won 5-2 in the previous matchup. Anthony Cirelli led the Lightning with two goals. TOP PERFORMERS: Nikita Kucherov has 11 goals and 17 assists for the Lightning. Emil Martinsen Lilleberg has scored goals over the past 10 games. Nathan MacKinnon has scored seven goals with 28 assists for the Avalanche. Sam Malinski has over the last 10 games. LAST 10 GAMES: Lightning: 4-4-2, averaging 3.4 goals, six assists, 3.4 penalties and 9.3 penalty minutes while giving up 2.8 goals per game. Avalanche: 7-3-0, averaging 3.5 goals, 6.2 assists, 2.9 penalties and 5.8 penalty minutes while giving up 2.6 goals per game. INJURIES: Lightning: None listed. Avalanche: None listed. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .... The Independent National Electoral Commission (INEC) has said part of its measures to strengthen the electoral system is to phase out the Permanent Voter’s Cards (PVCs), as means of voter identification on election day. INEC Chairman, Prof. Mahmood Yakubu, at a meeting with Resident Electoral Commissioners (REC) in Abuja on Thursday, disclosed that 142 areas of amendments were identified from the recommendations contained in the 524-page report on the conduct of the 2023 general elections. The recommendations, according to him, include the general state of preparedness, voter management, voter education and public communication, political parties and candidate management. Others include electoral operations and logistics management, election officials and personnel, partnership and collaboration, monitoring and supervision, election technology, voting and result management, election security, electoral offences and the electoral legal framework. “There are eight recommendations that require legislative action by the National Assembly,” he said. Prof. Yakubu stated that out of this number, 86 of the recommendations require administrative action by the commission, stating that “very soon, the commission will make a presentation to the joint committee of the Senate and House of Representatives on Electoral Matters as they continue to deliberate on electoral reform.” According to him, with the introduction of the Bimodal Voter Accreditation System (BVAS), the use of the permanent voters’ cards (PVC) as the sole means of identification for voter accreditation on election day should be reviewed. Though he assured that those who already have the PVCs could still use them to vote, “but going forward, computer-generated slips issued to the voter or even downloaded from the Commission’s website will suffice for voter accreditation.” The INEC Chairman said this will not only save cost, it will also eliminate the issues around the collection of PVCs and the practice of buying up the cards from voters in order to disenfranchise them. He disclosed that the commission intends to review the mechanisms for a more effective implementation of agreements on logistics with the transport unions and other service providers, and said INEC will consolidate on its recent experience in Ondo State governorship election. “Similarly, the commission will step up action on voter access and distribution to polling units. “As a matter of urgency, the commission also intends to develop protocols for the cleaning up of the voters’ register in collaboration with other agencies such as the National Identity Management Commission (NIMC) and the National Population Commission (NPC). “Other areas of reform include advocacy for affirmative action for greater participation of under-represented groups, a more robust voter education and public communication to combat fake news and misinformation,” he stated. Prof. Yakubu noted that there were also recommendations in support of diaspora voting, the unbundling of INEC with the establishment of electoral offences tribunal and a separate agency to handle the registration and regulation of political parties. He further noted that the recommendations noted that INEC officials, security personnel, ad hoc staff, observers and journalists who are deployed outside the places where they registered to vote, do not vote in elections. Prof. Yakubu stated that the meeting with the RECs was because of their frontline role in the implementation of the recommendations. The INEC Chairman said that 48 recommendations of the report require action by a variety of stakeholders, including security agencies, mobile network operators, statutory bodies, political parties, transport unions, civil society organisations and the media. He stated that the meeting with the REC would focus on issues of planning and reform learning from the experience of the 2023 general election. “Having released our 524-page main report on the election, a copy of which is available on our website, we have consulted widely internally with our own officials and externally with all major stakeholders. “With the conclusion of five major off-cycle Governorship elections and nine out of 21 bye-elections since the 2023 general election, this is the most appropriate time for us to commence the implementation of the recommendations arising from our review of the general election,” he added.

The Trump family is celebrating a historic year. Donald Trump was selected as Time Magazine's Person of the Year, an achievement that he celebrated today in New York, ringing in the New York Stock Exchange Bell. Trump was joined by his closest advisors and family members, including his wife Melania , and two of his kids, Ivanka and Tiffany . Ivanka Trump shares sweet moment with her kids while gardening: 'Spending time together with our hands in the dirt' Melania Trump praises son Barron for 'giving advice to his father' Donald Trump The ringing of the bell took place earlier today, December 12th, on Wall Street. Photographers captured the moment when Trump rang the bell, dressed in a blue suit that he paired with a burgundy tie. Tiffany, Melania, and Ivanka also wore suits, with Tiffany and Ivanka opting for black while Melania opted for a gray look. In the background, Trump's Time cover can be seen, which showcases him posing with an arm over his leg in front of a gray background. Ivanka shared various photos and videos on social media, including the moment when Trump rang the bell and a photo of him signing the wall of the NYSE. "Celebrating an extraordinary milestone with my father as he rang the NYSE opening bell in front of his TIME Person of the Year cover," she wrote in the caption. "Congratulations, Dad!" Trump's honorific marks the second time he has been selected as Time's Person of the Year. He was previously selected in 2016 due to his unexpected political rise and his first election win. More details about Trump's appearance on Wall Street In a speech, Trump said it was an "honor" to ring the NYSE bell and he also laid out some of his plans for his incoming presidency. “We’re going to have a tremendous run. We have to straighten out some problems, some big problems in the world," he said. The event drew a large crowd to the area, with many stopping by to have a look at Trump and his closest advisors.

None

When the Washington Commanders play the Dallas Cowboys on Sunday, one of the primary storylines will be head coach Dan Quinn facing the team that employed him for the past three seasons. Due to his ties to both organizations, Quinn knows the magnitude of the Commanders/Cowboys rivalry is. In fact, he's known since he was just a kid. Quinn, who was raised in New Jersey, grew up in the 1980s watching the bitter battles of the NFC East. At the time, that included Bill Parcells' Giants, Buddy Ryan in Philadelphia, Tom Landry in Dallas and Joe Gibbs in Washington. Quinn has been known throughout his career as a motivator and a culture builder, and despite downplaying his own history in Dallas, it's clear he's well aware that this week means more than most other games for the Commanders. There's no doubt he will have his team extra fired up for Sunday. Several of Quinn's former pupils are also now Commanders, including Dante Fowler, Jr., Dorance Armstrong, Tyler Biadasz, Noah Igbinoghene and Noah Brown. Fowler, Armstrong and Igbinoghene worked with Quinn specifically on the defensive side of the ball. As for those still in Dallas, it doesn't seem there are any hard feelings towards Quinn from his former players despite his defection to the divisional foe. Micah Parsons and Malik Hooker both spoke highly of him , claiming he remains in touch with them. Suffice to say, Sunday will mean a lot for all parties involved -- even by Commanders vs. Cowboys standards.

Liga leaders Barca suffer late collapse in Celta draw

Principal Financial Group Inc. Invests $675,000 in UMH Properties, Inc. (NYSE:UMH)Trump asks Supreme Court to delay TikTok ban so he can weigh in after he takes office

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.Empowered Funds LLC Acquires 7,906 Shares of NL Industries, Inc. (NYSE:NL)Revitalized Dolphins carry momentum into Houston

NFL world reacts with excitement, surprise, questions after Bill Belichick is hired to coach UNC

United, Apple rolling out new way to track lost luggage with AirTags

Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to “Market Perform” at William Blair

Broken Arrow School Board Candidate Announces Public Meet and GreetClinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding

Previous: randy lol646 //
Next: referral code lol646